The so-called “Lead Compound Analysis” is the primary legal framework for assessing chemical obviousness. Despite the USPTO Patent Trial and Appeal Board’s (PTAB) initial apparent.
Global Drug Delivery Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
IAM
The Long Read
Life sciences companies are frequently on the front line when it comes to being flexible on IP and pricing, says Ben Bourke of Womble Bond Dickinson. The most recent example of this is Moderna Therapeutics’ promise not to enforce patents relating to its approved covid-19 vaccine. Such a response makes sense and should be favoured over government-led initiatives to circumvent IP rights. Read more here
MONDAY 5th April
A look at Chinese companies’ semiconductor patent holdings suggests that their best bet for gaining globally relevant IP in the space is to acquire it. However, that leaves them with a big problem. Read more here
Argentum Pharmaceuticals and Bausch Health Settle Patent Dispute Over JUBLIA®
News provided by
Share this article
Share this article
NEW YORK, Jan. 13, 2021 /PRNewswire/ Argentum Pharmaceuticals LLC, a generic pharmaceutical company, announced that it has reached a settlement agreement with Bausch Health US, LLC and Kaken Pharmaceutical Co., LTD., related to Argentum s inter partes review petition challenging an Orange Book-listed patent for JUBLIA® (efinaconazole) Topical Solution.
Argentum filed its IPR petition against U.S. Patent 7,214,506 (the 506 Patent ) on May 12, 2017. Argentum and Kaken entered into a confidential settlement agreement and filed a joint motion to terminate Argentum s IPR on November 12, 2020, prior to a decision on Argentum s petition by the Patent Trial & Appeal Board. On January 8